ConductScience.org, home

Trial · NCT02257567

Adverse events4,598

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEvents
otherNEUTROPENIABlood and lymphatic system disordersArm D (Phase II Randomization): BR in DLBCL213963
otherNEUTROPENIABlood and lymphatic system disordersArm E (Phase II Expansion): Pola+BG in FL62010
otherNEUTROPENIABlood and lymphatic system disordersArm F (Phase II Expansion): Pola+BG in DLBCL62030
otherNEUTROPENIABlood and lymphatic system disordersArm G+H (Phase II NF Cohort): Pola+BR in DLBCL3510673
otherPANCYTOPENIABlood and lymphatic system disordersCohort 1a (Phase Ib Safety Run-In): Pola+BR in FL060
otherPANCYTOPENIABlood and lymphatic system disordersCohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL161
otherPANCYTOPENIABlood and lymphatic system disordersCohort 1b (Phase Ib Safety Run-In): Pola+BG in FL161
otherPANCYTOPENIABlood and lymphatic system disordersCohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL161
otherPANCYTOPENIABlood and lymphatic system disordersArm A (Phase II Randomization): Pola+BR in FL0380
otherPANCYTOPENIABlood and lymphatic system disordersArm B (Phase II Randomization): BR in FL0410
otherPANCYTOPENIABlood and lymphatic system disordersArm C (Phase II Randomization): Pola+BR in DLBCL0390
otherPANCYTOPENIABlood and lymphatic system disordersArm D (Phase II Randomization): BR in DLBCL1391
otherPANCYTOPENIABlood and lymphatic system disordersArm E (Phase II Expansion): Pola+BG in FL0200
otherPANCYTOPENIABlood and lymphatic system disordersArm F (Phase II Expansion): Pola+BG in DLBCL1201
otherPANCYTOPENIABlood and lymphatic system disordersArm G+H (Phase II NF Cohort): Pola+BR in DLBCL21062
otherTHROMBOCYTOPENIABlood and lymphatic system disordersCohort 1a (Phase Ib Safety Run-In): Pola+BR in FL162
otherTHROMBOCYTOPENIABlood and lymphatic system disordersCohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL262
otherTHROMBOCYTOPENIABlood and lymphatic system disordersCohort 1b (Phase Ib Safety Run-In): Pola+BG in FL161
otherTHROMBOCYTOPENIABlood and lymphatic system disordersCohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL161
otherTHROMBOCYTOPENIABlood and lymphatic system disordersArm A (Phase II Randomization): Pola+BR in FL3386

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02257567/events?page=3